Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention AstraZeneca, the most common co-covered peer. We currently track 1 Biotech story that mention Lexicon Pharmaceuticals, all published on March 4, 2026.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention AstraZeneca, the most common co-covered peer. We currently track 1 Biotech story that mention Lexicon Pharmaceuticals, all published on March 4, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lexicon Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Lexicon Pharmaceuticals is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of heart failure drug Inpefa and the regulatory path for sotagliflozin in Type 1 Diabetes. The briefing examines the company's financial health and the strategic importance of its neuropathic pain candidate, LX9211.
Lexicon Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
